A PYMNTS Company

Marlboro Maker Takes Over UK Asthma Inhaler Maker Vectura For $1.1B

By  |  September 16, 2021
Marlboro

Cigarette giant Philip Morris International has taken control of Vectura, a UK firm that makes medicine and, of all things, devices to treat respiratory illnesses, after a US$1.1 billion bid. PMI, which manufactures Marlboro and Parliament brand cigarettes, said in a statement on Thursday, September 16, that roughly 75% of Vectura’s shareholders had tendered their support for the deal. 

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    Subscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    “We are very excited about the role Vectura will play in our Beyond Nicotine strategy,” Jacek Olczak, PMI’s CEO, said. The takeover is part of the cigarette group’s long term strategy to become a “broader healthcare and wellness” company with “smoke-free” products.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    Nevertheless, the deal has raised hackles at health groups like the British Lung Foundation, Cancer Research UK, and Asthma UK. Reps have questioned whether it is ethical for a tobacco company to own a company that looks to treat the diseases associated with smoking cigarettes, saying it creates “perverse incentives.” 

    The two organizations sent a letter of protest to the British government, co-signed by 35 medical professionals and charities. Olczak told The Telegraph last month that critics were “not interested in progress” and simply “settling old scores” with his industry.

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.